Moderna (NASDAQ:MRNA) is most famous for its quick development of a coronavirus vaccine. But the biotech was developing vaccines for other diseases before the pandemic and will be developing vaccines long after COVID-19 is a distant memory. In this video from Motley Fool Live, recorded on March 1, Fool.com contributors Brian Orelli and Keith Speights discuss the biotech's current pipeline and what investors should be looking forward to in the months and years to come.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,